Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pyxis Oncology, Inc. - Common Stock
(NQ:
PYXS
)
1.150
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pyxis Oncology, Inc. - Common Stock
< Previous
1
2
Next >
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
December 18, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in Upcoming Investor Conferences
November 03, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
November 03, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
October 13, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
October 09, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in September Investor and Industry Conferences
August 21, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
May 14, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
April 25, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 02, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
March 25, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 18, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
March 03, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
February 26, 2025
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with...
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
February 04, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
December 19, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
November 20, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
November 12, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201
November 11, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
August 29, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
August 14, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 28, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
June 10, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
May 30, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
May 14, 2024
From
Pyxis Oncology
Via
GlobeNewswire
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
May 09, 2024
From
Pyxis Oncology
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
